throbber

`
`
`
`Annu.Rey.Biochem.1974.43:509-538.Downloadedfromwww.annualreviews.org
`
`
`
`
`
`
`
`y.agr.comon12/15/21.Forpersonaluseonl
`
`‘ws
`
`byportega(
`
`Copyright 1974, All rights reserved
`
`PEPTIDE HORMONES
`
`* 856
`
`Howard S. Tager' and Donald F. Steiner
`Department of Biochemistry, University of Chicago, Chicago, Illinois
`
`
`
`CONTENTS
`509
`INTRODUCTION wo. ccc ccc e cnet e een eee eeepc rene eee ee eee state teeneee
`510
`INSULIN 2.0 ccc cee eee teen eect eens ene e eben eee e eee eneeeeee
`514
`NONINSULIN INSULIN-LIKE PROTEINS 20.00.0000 cece eee eee eee ee eee eee eee anes
`$15
`GROWTH HORMONE, PROLACTIN, AND PLACENTAL LACTOGEN ....0..- 0.000 s eee eeee
`GLYCOPEPTIDE HORMONES... 02.000 ce tee tenet eee 517
`GLUCAGON AND RELATED HORMONES ........ 0000 cce scene penne en ee teen eeaenee
`§22
`GASTRIN AND RELATED HORMONES... 0-00.00 c eee cece ee eee ee tenet eee nee
`525
`CORTICOTROPIN, MELANOTROPIN, AND LIPOTROPIN........00 000000 e esac eee ecees
`526
`PARATHYROID HORMONE... 0000000 ccc eee ee eet e etn e eben ene t tne enee
`§28
`CONCLUDING REMARKS... 0.0: eee ccc tee ene erence eee eee ee een eee eee
`§30
`
`INTRODUCTION
`
`The last comprehensivereview in this series on the biochemistry ofpeptide hormones
`appeared in 1969 (1). However, various aspects of this subject have been reviewed
`frequently in the Annual Reviews of Biochemistry, Physiology, Pharmacology, and
`Medicine, as well as in other review series including Recent Progress in Hormone
`Research, Hormonal Proteins and Peptides, and Vitamins and Hormones. This volume
`includes a review of peptide hormone binding to cellular constituents and the
`possible relationship of this phenomenonto their biological effects (2), The Atlas
`of Protein Sequence and Structure by Dayhoff is also a valuable source for
`comparisons of primary structural relationships among various peptide hormones.
`In view of the breadth of this topic, our discussion is limited to structural and
`biosynthetic studies; peptide hormonesecretion and action are not considered. This
`is necessitated by the abundance of new information and concepts in all
`these
`areas. Rapidly accumulating sequence’ information on peptide hormones has
`provided interesting new clues to evolutionary and functional
`interrelationships
`among many hormones. Thus, several groups of related peptide hormones appear
`to have evolved from a relatively small number of ancestral proteins. Likewise,
`
`‘ Present Address: Department of Biochemistry, Medical College of Ohio, Toledo,
`Ohio 43614.
`
`? Published by the National Biochemical Research Foundation, Silver Spring, Md. The
`last comprehensive edition appeared in 1972 (Vol. 5), Supplements are published annually.
`
`509
`
`MSNExhibit 1027 - Page 1 of 32
`MSNv. Bausch -
`IPR2023-00016
`
`

`

`Annu.Rev.Biochem.1974.43:509-538.Downloadedfromwww.annualreviews.orgbyportega@wsgr.comon12/15/21.For
`
`
`
`
`
`personaluseonly.
`
`510
`
`TAGER & STEINER
`
`recent biosynthetic studies of a variety of endocrine peptides indicate that the
`primary gene productsdiffer significantly from the known peptide hormones.In at
`least six cases these peptides appear to be synthesized from larger precursors, and
`multiple molecular
`forms of the same hormone,
`representing biosynthetic
`intermediates as well as metabolites, may circulate in the blood. These new
`findings have altered earlier notions regarding the evolution, biosynthesis, and
`active forms of peptide hormones.
`
`INSULIN
`
`The last three to four years have seen considerable progress in elucidating the
`mechanism ofinsulin biosynthesis and in isolating and characterizing proinsulin
`(3, 4) and related peptide products from various species.
`It
`is now firmly
`established that proinsulin is synthesized on ribosomes in the rough endoplasmic
`reticulum of the £ cells (S-7) and that the precursor is then transferred via an
`energy-dependent process
`to the Golgi apparatus (8-11), where proteolytic
`conversion to insulin begins (12-15). Conversion continues to about 95%
`completion over a period of hours within newly formed secretory granules after
`they have formed by budding from the inner lamallae of the Golgi apparatus
`(7, 13-15). The process may be terminated at this stage by cocrystallization of the
`insulin with the residual proinsulin and intermediate products (16), giving rise to the
`dense crystalline granule inclusion that can be seen by electron microscopy
`within mature granules (17, 18). This small amount of proinsulin retained within
`the granules is secreted subsequently with insulin and has been identified in the
`circulation of man and animals (19-22).
`The conversion process has been studied in greater detail in secretion granule
`fractions isolated from islets prelabeled with radioactive amino acids in vitro
`(7, 12-15). Conversion in these particles exhibits a relatively sharp pH optimum
`at or slightly above pH 6.0 (15, 23). At least two kindsof proteolytic activity appear
`to be required for the conversion of proinsulin to insulin. The first is an endo-
`peptidase with trypsin-like specificity which cleaves on the carboxyl side of the
`pairs of basic residues that link the connecting polypeptide chain to the termini of
`the insulin A and B chains (4, 24). The second is an exopeptidase having specificity
`similar to carboxypeptidase B, which removes the C-terminal basic residues from
`both insulin and the C peptide? (25). Both kinds of activities have been
`demonstrated in disrupted secretion granule preparations (7, 15), and the endo-
`peptidase activity may be associated with the secretion granule membrane(7).
`Further support for this localization of the proinsulin converting enzymes within
`the B cells has been obtained in electron microscopic histochemical studies (26).
`Sufficient amounts of these enzymes for more detailed chemical characterization
`
`3The arrangement of the mammalian proinsulin polypeptide chain is: NH,-A
`chain: Arg: Arg - C-peptide - Lys: Arg: B chain-COOH. The C peptide thus becomes that
`portion of the connecting peptide sequence, aside from the pairs of basic residues at the
`ends, which is removed in the conversion to insulin (14).
`
`MSNExhibit 1027 - Page 2 of 32
`MSNv. Bausch - IPR2023-00016
`
`

`

`Annu.Rev.Biochem.1974.43:509-538.Downloadedfromwww.annualreviews.orgbyportega@wsgr.comon12/15/21.For
`
`
`
`
`
`personaluseonly.
`
`PEPTIDE HORMONES
`
`511
`
`have not been obtained from 8 granules, and studies with a variety of proteolytic
`inhibitors have been inconclusive in establishing their relationships to other known
`trypsin-like enzymes or carboxypeptidases (15). A further complication arises from
`the recent finding that a chymotrypsin-like cleavage occurs in rat connecting
`peptides during their proteolytic excision in incubated whole rat islets (27). These
`results suggest that the secretory granules maycontain low levels of several kinds of
`proteolytic enzyme activities. Specificity of cleavage thus may be determined as
`much bytertiary structural features of the substrates as by special adaptations of
`the proteases. An enzyme that converts proinsulin has been isolated from whole
`pancreas,butit has not been fully characterized with respect to eitherits origin in the
`islet tissue of the pancreasorits cleavage specificity and mechanism ofaction (28).
`In view of a recent report that immunoglobulin chains having extended amino-
`terminal regions are synthesized during in vitro translation of myeloma cell MRNA
`fractions (29), one might inquire whether insulin precursors larger than proinsulin
`also exist. However,aside from someevidencefor the expectedrole of an N-terminal
`residue of methionine in the initiation of proinsulin synthesis in fetal calf pancreas
`(30), no convincing indications of larger precursors have been found. Islet polysomes
`active in proinsulin synthesis appear to be mainly trisomes,a size consistent with the
`expected mRNAlength of about 258 nucleotides required to encode the 86-residue
`proinsulin polypeptide (31).
`Comparative studies of insulin biosynthesis in the cod (32) and anglerfish (33),
`as well as in such primitive vertebrates as cyclostomes(34), indicate the formation
`and cleavage of a proinsulin similar in size to the mammalian proteins. A require-
`mentfor trypsin-like cleavage has been demonstratedfor bothof the fish proinsulins,
`and aninteresting intermediate cleavage form, having an N-terminal
`tripeptide
`A-chain extension, has been isolated from angler fish islets by Yamaji et al (35).
`A numberof reports have appeared on the biosynthesis, isolation, and characteriza-
`tion of intermediate forms of mammalian proinsulins in various species (15, 24, 27,
`36-40).
`The proinsulin C peptide, somewhat analogousto the activation peptide in some
`zymogen proteins, also has becomea focus of attention. Due to localization of the
`conversion process within secretion granules,
`the C peptide accumulates with
`insulin in equimolar amounts (41) and is secreted along with the hormone by
`exocytosis of the granule contents (42). C peptides from nine mammalian and one
`avian species have beenisolated and sequenced (41, 43-50). A high rate of mutation
`acceptance—much higher than the rate for insulin and approaching that for the
`fibrinopeptides (49)—as well as the appearance of deletions in more than one
`region of the C-peptide sequence, suggest that structural requirements in this
`portion of proinsulin are less stringent than in the hormonally active portion of
`the molecule. Whether or not biologically important functions other than efficient
`peptide chain folding, sulfhydryl oxidation, and specific enzymic cleavage are also
`encodedin this peptide remains unanswered.
`Synthesis of several mammalian C peptides has been accomplished recently by
`classical fragment condensation (51-56). The synthetic porcine C peptide, contain-
`ing all four terminal basic residues, was tested for its ability to promote the
`
`MSNExhibit 1027 - Page 3 of 32
`MSNv. Bausch - IPR2023-00016
`
`

`

`
`
`
`
`Annu.Rev.Biochem.1974.43:509-538.Downloadedfromwww.annualreviews.orgbyportega@wsgr.comon12/15/21.For
`
`personaluseonly.
`
`
`
`
`
`
`
`512
`
`TAGER & STEINER
`
`recombination of insulin A and B chains in vitro, but it failed to influence the
`yield (57). Synthetic porcine and bovine C peptides cross-react well with antibodies
`directed against the corresponding natural proinsulins or C peptides, and frag-
`ments of these peptides have been successfully utilized to study the antigenic
`determinants in this region of the proinsulin molecule (53, 54, 58).
`Both proinsulin and the Cpeptide have been detected in the circulation of man
`‘ and other species by means ofspecific immunoassays (for a review see 59). The
`level of proinsulin rises slowly after a glucose load in normal subjects but does not
`exceed 20% of the total insulin-like immunoreactive material. Although abnormal
`proportions or absolute concentrations of proinsulin have been found in obesity,
`chronic renal failure, and patients with severe hypokalemia, the major diagnostic
`significance of elevated proinsulin levels has been in detecting patients with f cell
`tumors (60). The immunoassayable C-peptide levels have been shown by Rubenstein
`and co-workers to mirror changes in insulin levels and thus provide a means for
`evaluating endogenousinsulin production in diabetic individuals in whom insulin
`antibodies and administered animal insulins invalidate direct insulin measurements
`(61, 62). The handlingofproinsulin and C peptide in vivo differs significantly from
`that of insulin (63, 64). This factor must be taken into consideration when
`interpreting changes in peripheral blood levels of immunoreactive insulin and in
`estimating the relative biological potency of proinsulin by means of in vivo blood
`glucose-lowering assays. The biological activity of proinsulin on fat cells (65) and
`muscle tissue (66) in vitro is about 3-5that of insulin. Higher activity is usually
`found in vivo, ranging from 20-30%, a result attributable to the slower turnover
`rate of proinsulin rather than to any proteolytic conversion of proinsulin to insulin
`in the circulation or tissues (59). The difference in turnover rates of proinsulin and
`insulin is due largely to the relatively greater uptake and degradation of insulin by
`the liver, a major site of insulin destruction in the intact organism (67). The precise
`enzymic mechanism ofinsulin degradation remains controversial despite a recent
`renewal of interest in this problem (68-71). The studies of Varandani and co-
`workers have brought forth new evidence implicating an initial step of reductive
`cleavage in this process (71-73).
`Therecent elucidation of the three-dimensional structure ofinsulin, initially at a
`resolution of 2.8 A (74, 75) and with recent refinements at 1.9 A (76) by Hodgkin
`and her co-workers, represents an important breakthrough in the study of peptide
`hormonestructure. It is beyond the scope of this review to describe this structure
`in detail or the growingliterature on the chemical and immunological properties and
`their structural correlations in normal, modified, or synthetic insulin molecules.
`Several recent reviews are cited (76-80). Modifications include the introduction of
`various substituent groups on the amino,histidyl, or carboxyl groups of insulin
`(76, 81-86), selective reduction and substitution of disulfide bonds (87), and the
`introduction of intramolecular crosslinks between the Al and B1, or Al and B29
`(e-lysine) amino groups (79, 88, 89). The latter group of derivatives, especially the
`series linked between Al and B29 by dicarboxylic acids (79), are of addedinterest,
`since these bridges simulate the naturally occurring connecting polypeptide in
`proinsulin. Adipoylinsulin,
`in which adipic acid serves to crosslink the amino
`
`MSNExhibit 1027 - Page 4 of 32
`MSNv. Bausch - IPR2023-00016
`
`

`

`Annu.Rev.Biochem.1974.43:509-538.Downloadedfromwww.annualreviews.orgbyportega@wsgr.comon12/15/21.For
`
`
`
`
`
`personaluseonly.
`
`PEPTIDE HORMONES
`
`§13
`
`groups of residues Al and B29, has been reduced and reoxidized in vitro under
`conditionssuitable for proinsulin reoxidation with comparable yields ranging up to
`75°% (90). These results indicate that the role of the connecting peptide in promoting
`correct pairing of half-cystine residues in proinsulin can be played by a non-
`peptide molecular prosthesis.
`Noneofthe insulin derivatives prepared to date have exhibited higher biological
`activity than insulin itself. As with proinsulin, assays often indicate higher activity
`in vivo than in vitro (79), suggesting that many of these analogs may accumulate
`to a greater extent in the blood as a result of their decreased susceptibility to
`degradation. This cannot be the case with the identical turkey and chicken insulins
`which exhibit 2-4 times higher activity than bovine insulin in several
`in vitro
`bioassay systems (91). Weitzel and co-workers suggest that this heightened activity
`may result from enhanced receptor binding due to the substitutions ofhistidine
`for alanine and asparagine for serine at positions A8 and AQ,
`respectively.
`Onthe other hand, substitution of the B5 histidine by alanine in a synthetic bovine
`insulin led to lowerbiological activity (92). Duck insulin mayhelp to clarify the role
`of substitutions in the A8—10 region in enhancing biological activity of chicken and
`turkey insulins. This avian species has glutamic acid at position A8 and proline at
`A10, and the B chain differs only at position 30 where threonine replaces alanine
`(93). Bioassay results have not yet been reported.
`In contrast, guinea pig insulin, which differs from porcine insulin at 17 positions
`(49), displays significantly lower biological activity in other mammals as well as in
`guinea pigs (94). In addition to altered molecular topography due to the amino
`acid changes, guinea pig insulin does not bind zinc and does not form dimers or
`higher polymers in solution (94). Associated with this rather drastic change in
`properties is the replacement by asparagine of the B10 histidine residue, which
`coordinates with zinc in two zinc porcine insulin crystals (74). By contrast, the two
`insulins in the mouse, an old-world rodent, closely resemble other mammalian
`insulins and are identical to those of the rat (95).
`.
`Anotherinsulin of considerable interest has been isolated from the islet organs of
`a primitive jawless vertebrate, the Atlantic hagfish (34, 96), an animal belonging
`to one of two extant orders of the cyclostomes, which are believed to have
`diverged from the gnathostomes about 600 million years ago (97, 98). Hagfish insulin
`has about 10° ofthe activity of bovine insulin in mammalian systems (96). About
`40° of its amino acid residues differ from those found in mammalian insulins,
`including replacementofthe zinc-binding B10 histidine residue by aspartic acid (99).
`Nevertheless,it forms large tetragonal crystals at pH 6.0 in the absenceof zinc (34).
`Almost all of the invariant residues in the known gnathostomian insulins (49),
`including the half-cystines, are conserved in hagfish insulin.
`Studies with selectively degraded or synthetic insulins indicate that the absence
`of the Al glycine amino group (100) or the Al glycine residue (79, 81) results in a
`loss of biological activity. In the absence of the Al-4 tetrapeptide sequence (101)
`or the C-terminal A21 asparagine residue (102, 103), biological activity is either
`absent or extremely low. Although C-terminal shortening of the B chain up to
`residue 27 does not affect the biological activity (104, 105), further deletions toward
`
`MSNExhibit 1027 - Page 5 of 32
`MSNv. Bausch - IPR2023-00016
`
`

`

`
`
`
`
`Annu.Rev.Biochem.1974.43:509-538.Downloadedfromwww.annualreviews.orgbyportega@wsgr.comon12/15/21.For
`
`personaluseonly.
`
`
`
`
`
`514
`
`TAGER & STEINER
`
`residue 22 (102) progressively reduce biological activity (104), suggesting that the
`region B22-26 may play an important
`role in biological activity (106) as
`well as in dimerization (76). Replacement of the cysteine residues providing the
`intrachain disulfide loop, between A6—11 with two alanine residues results in a
`product with about 10% of normalbiologicalactivity in vivo (107). X-ray diffraction
`studies are required to differentiate purely local from more generalized topo-
`graphical changes in these altered molecules, and thus delineate more precisely
`the region(s) required for cell binding and biological function.
`The three-dimensional structure of proinsulin has evoked considerable interest
`ever since the prohormone wasfirst isolated. Although it has been crystallized
`successfully in several forms by Low and co-workers (108, 109), the crystals have
`not been ofsufficient quality to permit extensive data collection. Preliminary X-ray
`diffraction analyses, however, confirm the results from other physical studies
`indicating that proinsulin aggregates similarly to insulin to form dimers and
`hexamersunder appropriate conditions (110, 111). The hypothesis that the insulin
`moiety ofproinsulin hasessentially the same conformationasinsulin is borne out by
`similarities in optical rotary dispersion (ORD)andcircular dichroism (CD)spectra,
`by the titration behavior ofthe tyrosine residues of both peptides (112, 113), and by
`the high degree ofimmunological cross-reactivity ofproinsulin with antisera to insulin
`(114, 115). Little evidence for the existence of ordered structure in the connecting
`peptide portion ofproinsulin has been obtained (112). The peptide is believed to be
`folded in some manneroverthe externalsurface of the insulin monomersin proinsulin
`hexamers, spanning the 8-10 A gap between the C terminus of the B chain and the
`N terminus of the A chain (16). Proinsulin and insulin evidently can form mixed
`polymers, which may account for the tendency of the prohormonetocrystallize with
`insulin during the commercial preparation of insulin (16).
`In addition to the studies on proinsulin mentioned above, recent structural
`investigations oninsulin and variousderivatives of insulin have utilized a variety of
`physical probes,including ORD and CD (103, 112, 116), Raman spectroscopy(117),
`electron paramagnetic resonance spectroscopy (118), and infrared spectroscopy
`(119). Recent evidence on the structure of insulin fibrils produced at elevated
`temperatures in acid solutions indicates that these are cross-B structures having a
`uniform cross-section of 29 x 47 A, and consisting of flattened insulin monomers
`packed heterologously in layers 4.7 A thick in the direction ofthefibril axis (120).
`
`NONINSULIN INSULIN-LIKE PROTEINS
`
`It has becomeincreasingly clear that proteins other than insulin can share many of
`its biological actions and may have additional physiological functions as well. One
`of these is the nonsuppressible insulin-like activity (NSILA)of plasmathat has been
`studied extensively by Froesch and co-workers (121, 122). Although it circulates
`normally as an inactive larger complex, a soluble active substituent of molecular
`weight about 7500 can be separated under acidic conditions. This single-chain
`peptide can compete weakly but effectively with insulin for receptor sites in
`membrane preparations (123, 124), and it reproduces all
`the known biological
`
`MSNExhibit 1027 - Page 6 of 32
`MSNv. Bausch - IPR2023-00016
`
`

`

`Annu.Rev.Biochem.1974.43:509-538.Downloadedfromwww.annualreviews.orgbyportega@wsgr.comon12/15/21.For
`
`
`
`
`
`personaluseonly
`
`PEPTIDE HORMONES
`
`515
`
`effects of insulin (125, 126). As suggestedfirst by Hall, recent evidence points to the
`probable identity of this substance with somatomedin, the new designation (127) for
`the well-known serum sulfation factor believed to be causally associated with the
`growth-promoting actions of growth hormone in vivo (124, 128-130). Although
`insulin, somatomedin, and perhaps the submaxillary gland nerve growth factor,
`which has some structural similarities to proinsulin (131), all produce basically —
`similar anabolic and mitogeniceffects, it is clear that nonidentical receptors with
`sharply differing binding specificities for these peptides exist in their various target
`tissues (124). Whether or not lowered cyclic AMP levels (130) can account for the
`spectrum ofresponseselicited by these distinctive groups of peptides is a question
`that requires much further study.
`
`GROWTH HORMONE, PROLACTIN, AND PLACENTAL
`LACTOGEN
`
`The primarystructures of mammalian growth hormones (GH)* have been actively
`investigated in recent years. The ovine hormone contains 189-191 residues (132, 133).
`The primary structure of bovine GH is practically identical to that of the ovine
`hormone (132-134). Partial séquences of porcine (135) and equine GH (136-138)
`suggest that as a group the ovine, bovine, porcine, and equine hormonesvary by less
`than 5% oftheir structure. The peptide chain of human GHis aboutthe same length
`as that of the ovine hormone,but less than two thirds ofits residues are homologous
`with ovine or bovine GH (139~142). This difference in structure probably accounts
`for the lack of bovine GH activity in man (143). The mammalian growth hormones
`contain two disulfide bridges: one spans 110 residues and joins cysteine residues
`53-164; the other spans only six residues and joinsresidues 181 and 189.
`Two other peptide hormones show remarkable structural similarities with GH.
`The chorionic hormone, placental lactogen, contains 191 residues, 85° of which are
`homologouswith those of human GH (140, 144, 145). This near identity in primary
`structureis reflected by a similar placementof disulfide bridges and some similarities
`in biological activity. Since the placental lactogen appears to possess a portion of
`the activity of human GH in promoting growth, Li and his associates have suggested
`that
`it be called chorionic somatomammotropin (146). The other hormone
`exhibiting structural homology with GH is pituitary prolactin. The complete
`primary structures of both the porcine and ovine prolactins are now known (147-
`149). The bovine hormoneis probably nearly identical to the ovine (150). Despite
`earlier uncertainty as to the existence of a unique prolactin in the primate pituitary,
`the monkey (151) and human(152) hormoneshave recently been isolated, and the N-
`terminal sequence of the human hormone was determined by Niall et al (153).
`
`+The abbreviations used in this article are the following: GH, growth hormone
`(somatotrophic hormone); LH,luteinizing hormone(interstitial cell-stimulating hormone);
`FSH, follicle-stimulating hormone; TSH,
`thyroid-stimulating hormone; HCG, human
`chorionic gonadotropin; ACTH, adrenocorticotrophic hormone(corticotropin); MSH,
`melanocyte-stimulating hormone (melanotropin); LPH, lipotrophic hormone(lipotropin);
`and PTH, parathyroid hormone.
`
`MSNExhibit 1027 - Page 7 of 32
`MSNv.Bausch - IPR2023-00016
`
`

`

`
`
`
`
`Annu.Rev.Biochem.1974.43:509-538.Downloadedfromwww.annualreviews.orgbyportega@wsgr.comon12/15/21.For
`
`personaluseonly.
`
`
`
`
`
`516
`
`TAGER & STEINER
`
`Human amniotic fluid is a promising source for human prolactin (154). Ovine
`prolactin contains 198 amino acid residues and three disulfide bridges. Two of these
`appear to be homologouswith the disulfide bridges of GH. The other spansa six-
`residue sequence near the N terminus of the hormoneandis also present in human
`prolactin (153).
`Although the amino acid sequences of ovine GH and ovine prolactin show less
`than 30% homology, many of the apparent amino acid interchanges appear to be
`relatively conservative when viewed either by side-chain functionality or by the
`numberof nucleotide base changes necessaryto alter the appropriate codons (140,
`147). A common evolutionary origin of prolactin, placental lactogen, and growth
`hormone has been suggested (140). Even more provocative is the suggestion by
`Niall and co-workers that
`these peptide hormones contain internal structural
`homology (140). On this basis, they propose that the three hormones may have
`arisen from repeated tandem duplications of a gene coding for a relatively small
`peptide (140).
`functional similarities of GH and prolactin in mammals are
`The partial
`paralleled by their similar actions in lower vertebrates (155). Ovine prolactin and
`ovine GH are both potent somatotropins in a variety of such species, including
`teleost fishes and reptiles. The growth hormonepresent in the pituitaries of modern
`teleosts is apparently ineffective in mammals, however (156). The pituitaries of birds,
`reptiles, and amphibians appear to contain separate prolactin-like and growth
`hormone-like hormones(155). The biological significance of these forms, especially
`the prolactins, is still unknown. Therecently isolated growth hormones from duck
`and turtle have remarkably similar amino acid compositions which differ only
`slightly from that of human GH (157).
`Prolactin, placental lactogen, and GH also share some features of secondary
`structure, as determined by CD,fluorescence, and titration behavior (158-160).
`Each of the three hormones contains about 50° « helix and all undergo similar
`structural transitions in acid or base. Aloj & Edelhoch have found that human GH
`is less easily denatured than bovine GH orovineprolactin by treatment with acid
`or urea (160). The single tryptophan residue in placental lactogen appears to be
`more exposed to the solvent than is the corresponding residue in human GH(159).
`Likewise, this tryptophan residue appears to be more exposed in human than in
`bovine GH (161, 162). Cambiaso and co-workers interpret
`rates of proton
`exchangeasindicating that the structure of human GHis more openthanthatofthe
`bovine hormone (163). Thusrelatively small structural or conformational changes
`may account for the lack of activity of bovine GH in man.
`Controversy continues to surround the question of the biological activity of
`various fragments of growth hormone. Bornstein and co-workers claim to have
`isolated two peptides having opposing biological activities after limited proteolysis
`of human GH (164). A C-terminal, 25-residue fragment of the hormoneis reported
`to be diabetogenic, while a smalier N-terminal fragment of the hormone appears to
`have an insulin-like effect (164, cf 140). However, Schwartz has reported that a
`cyanogen bromide fragment of human GH containing the C-terminal 21 residues
`lacks the inhibitory actions of Bornstein’s 25-residue fragment on several glycolytic
`enzymesin vitro (165).
`
`MSNExhibit 1027 - Page 8 of 32
`MSNv.Bausch - IPR2023-00016
`
`

`

`Annu.Rev.Biochem.1974.43:509-538.Downloadedfromwww.annualreviews.orgbyportega@wsgr.comon12/15/21.For
`
`
`
`
`
`personaluseonly
`
`PEPTIDE HORMONES
`
`517
`
`In the case of bovine GH, a 37-residue tryptic fragment derived from the large
`disulfide loop of the hormone appears to have some growth-promoting activity,
`even in man (166, 167). This peptide as isolated by Sonenberg et al is partially
`homologouswith a similar sequence of human GH and mayincludethe active core
`of the hormone. Another fragment of humanor bovine GH, consisting of residues
`5~117 and containing a single residue of aminoethylcysteine, exhibits some of the
`biological properties of the intact hormone (168), but does not stimulate skeletal
`growth. Synthetic sequences of human GH representing residues 87-123 and
`residues 124-155 appear to have growth-promoting activity in rats (169). In the
`course of studies of the biological activities of GH fragments, several incorrect
`sequences have been synthesized (164, 170, cf 140 and 169). That these peptide
`analogs possess some biological activity suggests that considerable latitude is
`allowed in the recognition of active forms.
`Several recent reports suggest that circulating human GH consists of GHitself and
`a considerably larger form, which usually makes up 10-30% of the plasma
`immunoreactivity. Since this large GH is dissociated to GH by urea or by various
`physical treatments, it may represent a GH aggregate or GH bound to a larger
`protein, rather than a precursor. Such large forms of immunoreactive GH are also
`found in human, rat, and dog pituitary glands (171-173). The physiological
`significance of the large form is not known. A similar large form of placental
`lactogen has been detected in:human pregnancy serum and in extracts of human
`placenta (174).-
`
`GLYCOPEPTIDE HORMONES
`
`Since the ciscovery that the treatmentof ovine luteinizing hormone (LH)with dilute
`acid results in the dissociation of the hormoneinto dissimilar subunits (175, 176),
`considerable effort has been expended inisolating this glycopeptide hormone from
`a variety of sources. The dissociated subunits have been separated from each other
`by countercurrent distribution (177) or by various chromatographic procedures
`(178). The « subunits of ovine (179, 180), porcine (181), and bovine (182-184) LH
`contain 96 amino acid residues, whereas the « subunit of human LH appearsto
`’ contain only 89 residues (185). Carbohydrate is attached at asparagine residues 56
`and 82 of the three nonprimate subunits and at
`the homologous asparagine
`residues 49 and 75 of the human subunit.
`The primary structures of ovine LH-~~ as reported by Sairam, Papkoff & Li (180)
`and by Liu and associates (179) differ only by an inversion at positions 88 and 89.
`The formergroup proposes the sequence Cys-Ser, whereasthe latter suggests Ser-Cys.
`The homologous sequence reported for human LH-a is Ser-Cys (185), but the
`sequence reported for bovine LH-« and HCG-« is Cys-Ser (182, 183, 186). The
`« subunit of ovine LH appears to be markedly heterogeneousat its N-terminus, due
`to deletion ofup to eight of its N-terminal residues (179). An apparent 7-residue
`deletion at the N terminus of human LH-«, when compared to ovine LH-a, has
`been well documented (185, 187, 188). Whether this is a true deletion or an
`artifact due to-proteolytic degradation during isolation is uncertain.
`A comparison of primary structures shows the « subunits of bovine and ovine LH
`
`MSNExhibit 1027 - Page 9 of 32
`MSNv. Bausch - IPR2023-00016
`
`

`

`
`
`
`
`Annu.Rev.Biochem.1974.43:509-538.Downloadedfromwww.annualreviews.orgbyportega@wsgr.comon12/15/21.For
`
`personaluseonly.
`
`
`
`
`
`518
`
`TAGER & STEINER
`
`to be identical, while the porcine subunit differs from these by only 5, and the
`human by 23, residues. Many amino acid sequences within the subunits from
`different species remain invariant, the longest blocksof identity being 14, 11, and 8
`residues. The 10 cysteine residues and their homologous positions also remain
`unchanged.
`The carbohydrate content ofLH hasbeendifficult to assess. The total carbohydrate
`andthe relative proportions of hexoses, fucose, hexosamines, andsialic acid appear
`to differ among the human (188, 189), ovine (190), bovine (191), and equine
`hormones(192). The equine hormone appears to be unusually high insialic acid.
`Alterations in the carbohydrate content, particularly in sialic acid, have been
`proposed as an explanation for microheterogeneity in human LH (193).
`The primary structure of the 8 subunit of ovine LH as determined by Liuet al
`(194) differs from

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket